Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|107|9|1281-1289

ISSN： 1347-9032

Source： Cancer Science, Vol.107, Iss.9, 2016-09, pp. : 1281-1289

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

By  

Cancer Science, Vol. 106, Iss. 11, 2015-11 ,pp. : 1561-1567

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 611-617

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1714-1721

John Wiley & Sons Inc

Access to resources Recommend Favorite